Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 28, 2025
Deals
Abbvie seeks molecular glue degraders from Neomorph
Also in BioCentury’s Deals Report, Novo licenses BACH1 inhibitor from Immvention, Arrivent-Lepu in ADC deal, and Sage rejects Biogen’s bid
BioCentury | Jan 6, 2025
Regulation
2024 Approvals: Where are the new modalities?
Last year’s new drug approvals by FDA reflect the continued focus on best-in-class drug development
BioCentury | Jan 3, 2025
Product Development
Axsome to lean on totality of data in Alzheimer’s agitation submission
Company looks to expand the label of depression drug AXS-05, while bringing Alzheimer’s agitation its second mechanism
BioCentury | Nov 19, 2024
Product Development
An understudied dementia soon to get a pair of Phase II readouts
CervoMed and Cognition Therapeutics testing different therapeutic hypotheses in dementia with Lewy bodies
BioCentury | Oct 9, 2024
Product Development
TYK2 best-in-class battleground expands with InnoCare data
In BioCentury’s latest Clinical Report: Sage misses in early Alzheimer’s, and a Phase III setback for J&J’s bladder cancer delivery device
BioCentury | Sep 4, 2024
Discovery & Translation
Immunoproteomics upstage genomics in I&I target discovery
Back to School 2024 identifies the target classes emerging in inflammation and immunology, and the technologies used to find them
BioCentury | May 22, 2024
Discovery & Translation
Science Spotlight: GLP1-NMDA for obesity, anti-ceramide for diabetic retinopathy, and more
BioCentury’s roundup of translational innovations
BioCentury | Apr 30, 2024
Distillery Therapeutics
Peptide blocking the TRPM2- PKCγ interaction for stroke
BioCentury | Mar 12, 2024
Deals
Deal report: Boehringer-Sosei pursuing new schizophrenia target
Plus: Gilead- Merus to develop trispecific T cell engagers for cancer, and Armatus-Solid collab
BioCentury | Mar 5, 2024
Discovery & Translation
Distillery spotlight: new Alzheimer’s mechanisms from academia
BioCentury’s survey of the 2023 translational literature highlights a cluster of neuron-targeting mechanisms for Alzheimer’s disease
Items per page:
1 - 10 of 669